Investors
Find Psyched Wellness on These Exchanges
Psyched Wellness is led by a strong team of experts, and currently engaged in Pre-Clinical Trials of AME-1, its proprietary extract of Muscimol.
PSYC
Canada - CSE
5U9
Frankfurt
PSYCF
OTCQB
Capital Structure
| Common Shares | 135,514,695 |
| Warrants | 23,886,365 |
| Options | 13,275,000 |
| RSU's | 4,650,000 |
| Fully Diluted | 177,701,060 |
| Issued and Outstanding | 135,789,695 |
The company has identified a path to market and is on track to commence commercialization of AME-1 derived products for the first half of 2022.
Why Invest in Psyched Wellness?
First to Market
Psyched Wellness is the first company to bring the Amanita Muscaria to the market for human consumption in a standardized and safe product
Proven Product
The product is backed by science, patented, and trademarked to Psyched Wellness
Responsible
We plan to have sustainable revenue from 2022 onwards
Company Overview
Psyched Wellness Ltd. Is a Canadian-based Life Sciences company focused on the research and development of a legal psychedelic mushroom called Amanita Muscaria. The company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.